Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on March 27, 2007
J Am Soc Nephrol 18: 1508-1515, 2007
© 2007 American Society of Nephrology
doi: 10.1681/ASN.2006121343

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006121343v1
18/5/1508    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boor, P.
Right arrow Articles by Ostendorf, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boor, P.
Right arrow Articles by Ostendorf, T.

Pathophysiology of Renal Disease and Progression

Complement C5 Mediates Experimental Tubulointerstitial Fibrosis

Peter Boor*,{dagger}, Andrzej Konieczny*, Luigi Villa*, Anna-Lisa Schult*, Eva Bücher*, Song Rong*, Uta Kunter*, Claudia R.C. van Roeyen*, Thomas Polakowski{ddagger}, Heiko Hawlisch{ddagger}, Sonja Hillebrandt§, Frank Lammert§, Frank Eitner*, Jürgen Floege* and Tammo Ostendorf*

* Division of Nephrology, Rheinische-Westfälische Technische Hochschule, University of Aachen, Aachen, Germany; {dagger} Department of Clinical and Experimental Pharmacotherapy, Research Base of Slovak Medical University, Bratislava, Slovakia; {ddagger} Jerini AG, Berlin, Germany; and § Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany

Address correspondence to: Dr. Tammo Ostendorf, Division of Nephrology and Immunology, University Hospital Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany. Phone: +49-241-8089424; Fax: +49-241-8082446; E-mail: tostendorf{at}ukaachen.de

Received for publication December 12, 2006. Accepted for publication February 7, 2007.

Renal fibrosis is the final common pathway of most progressive renal diseases. C5 was recently identified as a risk factor for liver fibrosis. This study investigated the role of C5 in the development of renal tubulointerstitial fibrosis by (1) induction of renal fibrosis in wild-type and C5–/– mice by unilateral ureteral ligation (UUO) and (2) investigation of the effects of a C5a receptor antagonist (C5aRA) in UUO. In C5–/– mice, when compared with wild-type controls, markers of renal fibrosis (Sirius Red, type I collagen, fibronectin, {alpha}-smooth muscle actin, vimentin, and infiltrating macrophages) were significantly reduced on day 5 of UUO. On day 10, fibronectin mRNA and protein expression were still reduced in the C5–/– mice. Cortical mRNA of all PDGF isoforms and of TGF-beta1 (i.e., central mediators of renal disease) were significantly reduced in C5–/– mice when compared with controls. Renal tubular cell expression of the C5aR was sparse in normal cortex but markedly upregulated after UUO. Treatment of wild-type UUO mice with C5aRA also led to a significant reduction of cortical Sirius Red staining, fibronectin protein expression, and PDGF-B mRNA expression on day 5. Neither genetic C5 deficiency nor C5aRA treatment caused any histologic changes in the nonobstructed kidneys. In cultured murine cortical tubular cells, C5a stimulated production of TGF-beta1, and this was inhibited by C5aRA. Using a combined genetic and pharmacologic approach, C5, in particular C5a, is identified as a novel profibrotic factor in renal disease and as a potential new therapeutic target.




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
F. Gueler, S. Rong, W. Gwinner, M. Mengel, V. Brocker, S. Schon, T. F. Greten, H. Hawlisch, T. Polakowski, K. Schnatbaum, et al.
Complement 5a Receptor Inhibition Improves Renal Allograft Survival
J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2302 - 2312.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Abbate, C. Zoja, D. Corna, D. Rottoli, C. Zanchi, N. Azzollini, S. Tomasoni, S. Berlingeri, M. Noris, M. Morigi, et al.
Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1158 - 1167.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP